CM5480 is an experimental therapy being developed by Calcimedica, a US clinical-stage biopharmaceutical company. The findings of a new study titled “Combination of Orai1 inhibitor CM5480 with specific therapy mitigates pulmonary hypertension and its cardiac dysfunction” reveals that CM5480 was helpful in rat models when used on its own and provided additional benefits when combined with two currently available pulmonary arterial hypertension treatment options.
CM5480 is designed to block the activity of Orai1, a protein that acts as a key part of calcium-regulating cellular machinery called calcium release-activated calcium (CRAC) channels. CRAC channels may play a role in pulmonary artery smooth muscle cell ing, which are key features of pulmonary arterial hypertension.
Read more at this link on Pulmonary Hypertension News